b) Excessively high parasympathetic activity
Rationale: Atropine is administered when parasympathetic activity is excessively high, such as in severe bradycardia, by blocking muscarinic receptors.
c) Autonomic ganglia of the ANS and NMJ
Rationale: Nicotinic receptors are located in the autonomic ganglia of the ANS, neuromuscular junctions (NMJ), and adrenal medulla.
b) Inhibitory
Rationale: In the heart, muscarinic receptors have an inhibitory effect, but they are excitatory in smooth muscle and glands.
b) Nicotinic receptors
Rationale: Ganglionic blockers like hexamethonium block nicotinic receptors, particularly at autonomic ganglia.
b) Blocking muscarinic receptors
Rationale: Atropine acts by blocking muscarinic receptors, thus reducing parasympathetic activity.
b) Excitation
Rationale: Muscarinic receptors are inhibitory in the heart but excitatory in smooth muscles and glands.
b) Excitation
Rationale: Nicotinic receptors at the NMJ and in autonomic ganglia primarily cause excitation.
c) Closed-angle glaucoma
Rationale: Atropine is contraindicated in closed-angle glaucoma due to the risk of increasing intraocular pressure.
b) Inhibition of adenylate cyclase and opening of potassium channels
Rationale: Muscarinic receptors in the SA node inhibit adenylate cyclase, leading to the opening of potassium channels.
b) Act as a neurotransmitter
Rationale: Acetylcholine is the primary neurotransmitter in the cholinergic system, playing a crucial role in various physiological functions.
b) Block nicotinic receptors at autonomic ganglia
Rationale: Hexamethonium acts as a ganglionic blocker by blocking nicotinic receptors at autonomic ganglia.
b) Increases heart rate
Rationale: Atropine is used in severe bradycardia to increase heart rate by reducing parasympathetic activity.
b) Increased intracellular IP3 and calcium
Rationale: Activation of muscarinic receptors in smooth muscles and glands leads to increased IP3 and intracellular calcium levels.
b) Increased adrenaline release
Rationale: Activation of nicotinic receptors at the adrenal medulla typically leads to increased adrenaline release.
b) Blocking muscarinic receptors
Rationale: Atropine increases sympathetic features by blocking muscarinic receptors, reducing parasympathetic activity.
c) Reduced neurotransmitter release
Rationale: Hexamethonium reduces neurotransmitter release by blocking nicotinic receptors at autonomic ganglia.
a) Decrease intraocular pressure
Rationale: Cholinergic drugs like Pilocarpine decrease intraocular pressure by enhancing the drainage of aqueous humor.
b) Increasing cardiac output
Rationale: Atropine is used in severe bradycardia to increase heart rate and cardiac output by reducing parasympathetic activity.
b) Decreased heart rate
Rationale: Muscarinic receptors in the heart primarily have an inhibitory effect, leading to a decreased heart rate.
a) Contracting smooth muscles
Rationale: Acetylcholine in the cholinergic system plays a role in contracting smooth muscles, among other functions.
c) Acetylcholine
Rationale: Acetylcholine is the primary neurotransmitter of the parasympathetic nervous system, responsible for stimulating parasympathetic activities.
a) Cholinergic Agonist
Rationale: Cholinergic agonists stimulate parasympathetic activity, leading to effects like decreased heart rate.
c) Adrenergic Agonist
c) Adrenergic Agonist
Rationale: Adrenergic agonists increase sympathetic responses, such as expanded airways, useful in asthma management.